LUNG CANCER

There is currently 1 FDA-approved antibody-drug conjugate available for patients with non-small cell lung cancer, and several more potentially coming down the pike.

An important clinical strategy that focuses on improved frontline EGFR TKI regimens may help combat acquired EGFR TKI resistance and further streamline treatment options in subsequent lines, according to Balazs Halmos, MD.

During a Case-Based Roundtable® event, Christine Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non-small cell lung cancer in the first article of a 2-part series.

Findings from recent clinical research have firmly entrenched the use of neoadjuvant immune checkpoint blockade in the treatment of early-stage non-small cell lung cancer.

In an interview with Targeted Oncology, Jonathan Spicer, MD, discussed the background and findings of the KEYNOTE-671 trial of perioperative pembrolizumab in non-small cell lung cancer.

Findings from the phase 3 METIS trial found that tumor-treating fields were able to significantly improve time to intracranial progression in patients with brain metastases from non-small cell lung cancer.

The combination of pembrolizumab and olaparib did not appear to improve overall or progression-free survival in patients with nonsquamous non-small cell lung cancer.

Data from the phase 3 POSEIDON trial support the use of tremelimumab, durvalumab, and chemotherapy for patients with metastatic non–small cell lung cancer, including harder-to-treat subgroups, in the first-line.

In the first article of a 2-part series, Christine Bestvina, MD, discussed the role of the newer tyrosine kinase inhibitor repotrectinib for patients with non–small cell lung cancer that is positive for a ROS1 mutation.

The FDA has accepted the new drug application of ensartinib for the treatment of patients with metastatic ALK-positive non-small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Misako Nagasaka, MD, PhD, asked participants how they would approach therapy for a patient with metastatic non–small cell lung cancer when biomarker testing is not yet completed. This is the second of 2 articles based on this event.

Third-line combination of THIO and cemiplimab improved overall response rate compared with standard of care in patients with non-small cell lung cancer.

Following the development of further safety and monitoring protocols, the IOV-LUN-202 trial can resume patient enrollment.

The FDA has granted a breakthrough therapy designation to BAY 2927088 for the treatment of non-small cell lung cancer harboring HER2-activating mutations.

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Hatim Husain, MD, explained the significance of the PACIFIC trial and its real-world counterpart PACIFIC-R looking at the use of durvalumab after chemotherapy and radiation in patients with unresectable stage III non–small cell lung cancer.

In 2 separate live virtual events, Firas B. Badin, MD, MBA, and Sandip P. Patel, MD, review a case of a patient with non–small cell lung cancer with their respective groups and discuss the best options for therapy.

In the first article of a 2-part series, Vamsidhar Velcheti, MD, MBA, discussed why patients with lung cancer may experience dizziness with repotrectinib and why the efficacy data behind this therapy are considered impressive.

During a Targeted Oncology™ Case-Based Roundtable™ event, Misako Nagasaka, MD, PhD, held a discussion on the use of biomarker testing in patients with advanced non–small cell lung cancer. This is the first of 2 articles based on this event.

The FDA has accepted the biologics license application of datopotamab deruxtecan for the treatment of nonsquamous non-small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sandip P. Patel, MD, and other oncologists discussed the role of chemotherapy plus dual immunotherapy in patients with non–small cell lung cancer.

The FDA has approved the combination of osimertinib plus chemotherapy for the treatment of EGFR-mutated non-small cell lung cancer.

The FDA has now fully approved tepotinib for the treatment of metastatic non-small cell lung cancer.

Participants in virtual events discussed the key issue of whether to initiate therapy immediately or wait for test results that could show the best approach in patients with advanced lung cancer.

In an interview, Martin F. Dietrich, MD, PhD, discussed his observations on the latest and upcoming trials that target biomarkers in earlier-stage non–small lung cancer.

Along with the FDA, the European Medicines Agency has also accepted the application of nivolumab and chemotherapy in operable non–small cell lung cancer.

A fast track designation to UV1 combination therapy for malignant mesothelioma from the FDA signifies expedited review and development for a promising treatment option, offering hope for patients with malignant pleural mesothelioma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Balazs Halmos, MD, discussed with participants how they interpret the ADAURA trial and the approach to adjuvant targeted therapy in non–small cell lung cancer This is the second of two articles based on this event.

In an interview with Targeted Oncology, Charu Aggarwal, MD, MPH, discussed the real-world study evaluating the link between molecular genotyping and survival among patients with non–small-cell lung cancer.

Patients with extensive-stage small cell lung cancer experienced longer rates of survival when treated with atezolizumab induction and maintenance therapy vs placebo.

The phase 3 EVOKE-01 trial of sacituzumab govitecan in non–small cell lung cancer missed its primary end point, showing a numerical but not significant improvement in overall survival.